Drug Profile

VIP 924

Alternative Names: BAY 924; VIP-924

Latest Information Update: 28 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bayer
Developer Bayer; Vincerx Pharma
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
Mechanism of Action Cyclin-dependent kinase 9 inhibitors; KIF11 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Mantle-cell lymphoma
No development reported B-cell lymphoma

Most Recent Events

28 Jun 2025 No recent reports of development identified for preclinical development in B-cell lymphoma in Germany (IV, Injection)
08 Aug 2024 Vincerx Pharma plans to submit IND application of VIP 924 in early 2026
10 Dec 2023 Pharmacodynamics data from preclinical studies in B-cell lymphoma released by Vincerx Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com